Philogen Provides Corporate Update 211 out of 214 patients recruited in European Phase III trial investigating the neoadjuvant Nidlegyâ„¢ treatment of Stage IIIB/C melanoma, in line with expectations.Fibromun further demonstrates potent activity in recurrent glioblastoma with durable major responses. Pivotal clinical trials in soft-tissue sarcoma and glioblastoma are on track.OncoFAP shows potent activity as a small molecule-drug conjugate.177Lu-BiOncoFAP therapy shown to eradicate cancer in pre-c
From:: Yahoo News – Sports